EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

  • ID: 3293067
  • Report
  • May 2015
  • 151 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Innovent Biologics, Inc.
  • Mabion SA
  • Panacea Biotec Limited
  • MORE
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015

Summary

This, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2015’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Ankylosing Spondylitis (Bekhterev's Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Ankylosing Spondylitis (Bekhterev's Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amgen Inc.
  • Biocon Limited
  • Celltrion, Inc.
  • Innovent Biologics, Inc.
  • Mabion SA
  • Panacea Biotec Limited
  • MORE
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Ankylosing Spondylitis (Bekhterev's Disease) Overview
Therapeutics Development
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Overview
Pipeline Products for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Ankylosing Spondylitis (Bekhterev's Disease) - Products under Development by Companies
Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development
Amgen Inc.
Avesthagen Limited
BIOCAD
Biocon Limited
Boehringer Ingelheim GmbH
Celgene Corporation
Celltrion, Inc.
Covagen AG
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Lupin Limited
Mabion SA
Momenta Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Protalix BioTherapeutics, Inc.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Therapeutic Proteins International, LLC
Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BI-655066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COVA-322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etanercept biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
golimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
golimumab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBI-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPM-004AM - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IBPM-005IX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
infliximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INV-17 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
secukinumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tofacitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ankylosing Spondylitis (Bekhterev's Disease) - Recent Pipeline Updates
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones
Featured News & Press Releases
Feb 16, 2015: Hospira launches first biosimilar monoclonal antibody Inflectra (infliximab) in major European markets
Nov 15, 2014: Novartis presents ground-breaking Phase III results showing AIN457 (secukinumab) significant efficacy in ankylosing spondylitis patients
Nov 10, 2014: Novartis to reveal landmark Phase III data for AIN457 (secukinumab) in psoriatic arthritis and ankylosing spondylitis at ACR 2014
Oct 23, 2014: Novartis AIN457 (secukinumab) meets primary endpoint in two Phase III studies in ankylosing spondylitis, a debilitating joint condition of the spine
Jul 09, 2014: Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA in Ankylosing Spondylitis
Sep 11, 2013: Hospira’s Inflectra the first biosimilar monoclonal antibody to be approved in Europe
Jun 27, 2013: Celltrion Healthcare Receives CHMP Positive Opinion For Remsima
May 31, 2013: Celltrion Provides Update On CT-P13 EU Approval Process
Mar 26, 2013: Celltrion Signs KRW88 Billion Contract With Celltrion Healthcare
Dec 14, 2012: Celltrion Signs KRW99 Billion Contract With Celltrion Healthcare
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2015
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Avesthagen Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by BIOCAD, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Boehringer Ingelheim GmbH, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corporation, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celltrion, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Covagen AG, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co., Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Johnson & Johnson, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Lupin Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mabion SA, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Panacea Biotec Limited, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Pfizer Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics, Inc., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) Therapeutics - Recent Pipeline Updates, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects (Contd..1), H1 2015
Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H1 2015
Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease) - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
3 of 4
Amgen Inc.
Avesthagen Limited
BIOCAD
Biocon Limited
Boehringer Ingelheim GmbH
Celgene Corporation
Celltrion, Inc.
Covagen AG
Epirus Biopharmaceuticals, Inc.
Genor BioPharma Co., Ltd.
Inbiopro Solutions Pvt. Ltd.
Innovent Biologics, Inc.
Johnson & Johnson
Lupin Limited
Mabion SA
Momenta Pharmaceuticals, Inc.
Novartis AG
Oncobiologics, Inc.
Panacea Biotec Limited
Pfizer Inc.
Protalix BioTherapeutics, Inc.
Sandoz International GmbH
Shanghai Pharmaceutical Co., Ltd.
Therapeutic Proteins International, LLC
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll